Saima Sultana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saima Sultana has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Joshua P. Vogel
Women's, Children's and Adolescents’ Health Program Burnet Institute Melbourne Australia
3 shared publications- Caroline Susan Elizabeth Homer
Burnet Institute, Melbourne, Victoria, Australia
2 shared publications - Joshua Peter Vogel
Burnet Institute, Melbourne, Victoria, Australia
2 shared publications - K M Saif-Ur Rahman
Evidence Synthesis Ireland and Cochrane Ireland, University of Galway, Galway, Ireland
2 shared publications Abdullah H Baqui
Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication- Abdullah H. Baqui
Department of International Health, International Center for Maternal and Newborn Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 24 November 2025
- Published by BMJ in BMJ Paediatrics Open
- Vol. 9 (1) , e003983
Antenatal dexamethasone for preterm birth and long-term health outcomes in children: a pilot follow-up cohort study of ACTION-I trial participants in Sylhet, Bangladesh
Background: The WHO ACTION-I trial in 2020 demonstrated the short-term efficacy and safety of antenatal dexamethasone for women at risk of early preterm birth in low-resource settings. However, the long-term effects of antenatal corticosteroids remain unclear, and no long-term follow-up studies have been conducted in low-resource settings. This pilot study aimed to evaluate the feasibility of participant follow-up from the ACTION-I trial and generate preliminary data on child health outcomes to inform the design of a larger follow-up cohort study within the trial population. Methods: A follow-up cohort study was conducted in Sylhet, Bangladesh, among children born to women enrolled in the ACTION-I trial at three hospitals. Eligible participants were 181 infants who had survived to 28 completed days after birth. The primary outcomes were participant follow-up rate and neurodevelopmental outcomes at 5 years’ corrected age. Results: Of the 181 eligible children, 160 (88%) were found and enrolled in this follow-up—78 from the dexamethasone group and 82 from the placebo group. Median Ages and Stages Questionnaire-Third Edition scores were similar between groups, except for a modest yet significant reduction in gross motor scores in the dexamethasone group (adjusted median difference: –5; 95% CI –8.7 to –1.3). Neurodevelopmental difficulties, particularly in fine motor and problem-solving domains, were the most common, affecting 39% and 34% of children in the dexamethasone group, and 33% and 36% in the placebo group, respectively. Behavioural and emotional problems were less common, with no significant differences between groups. Conclusions: Long-term follow-up of preterm infants in a low-resource setting is feasible. High retention rates, along with preliminary outcome estimates, provide a critical foundation for planning larger, more definitive cohort studies in similar settings. Furthermore, the high prevalence of neurodevelopmental difficulties in this population highlights the need for early childhood interventions and continued developmental surveillance.
- 24 November 2025
- Published by BMJ in BMJ Paediatrics Open
- Vol. 9 (1) , e003983
Open AccessAntenatal dexamethasone for preterm birth and long-term health outcomes in children: a pilot follow-up cohort study of ACTION-I trial participants in Sylhet, Bangladesh
Background: The WHO ACTION-I trial in 2020 demonstrated the short-term efficacy and safety of antenatal dexamethasone for women at risk of early preterm birth in low-resource settings. However, the long-term effects of antenatal corticosteroids remain unclear, and no long-term follow-up studies have been conducted in low-resource settings. This pilot study aimed to evaluate the feasibility of participant follow-up from the ACTION-I trial and generate preliminary data on child health outcomes to inform the design of a larger follow-up cohort study within the trial population. Methods: A follow-up cohort study was conducted in Sylhet, Bangladesh, among children born to women enrolled in the ACTION-I trial at three hospitals. Eligible participants were 181 infants who had survived to 28 completed days after birth. The primary outcomes were participant follow-up rate and neurodevelopmental outcomes at 5 years’ corrected age. Results: Of the 181 eligible children, 160 (88%) were found and enrolled in this follow-up—78 from the dexamethasone group and 82 from the placebo group. Median Ages and Stages Questionnaire-Third Edition scores were similar between groups, except for a modest yet significant reduction in gross motor scores in the dexamethasone group (adjusted median difference: –5; 95% CI –8.7 to –1.3). Neurodevelopmental difficulties, particularly in fine motor and problem-solving domains, were the most common, affecting 39% and 34% of children in the dexamethasone group, and 33% and 36% in the placebo group, respectively. Behavioural and emotional problems were less common, with no significant differences between groups. Conclusions: Long-term follow-up of preterm infants in a low-resource setting is feasible. High retention rates, along with preliminary outcome estimates, provide a critical foundation for planning larger, more definitive cohort studies in similar settings. Furthermore, the high prevalence of neurodevelopmental difficulties in this population highlights the need for early childhood interventions and continued developmental surveillance.
- Open Access
Antepartum fetal monitoring in pregnant women with diabetes: A systematic review
Diabetes in pregnancy affects approximately 15.5% of pregnant women worldwide, the majority of these women are in low‐ and middle‐income countries. Current guidelines recommend additional fetal monitoring for pregnant women with diabetes, particularly during the third trimester, though there is limited evidence supporting these recommendations. Our objective was to identify the optimal methods and regimens for antepartum fetal monitoring for pregnant women with diabetes to inform recommendations for future clinical practice. CENTRAL, Embase, MEDLINE, and LILACs databases were searched through 23 July 2024. There were no restrictions on language or publication type. We included randomized controlled trials (RCTs) or nonrandomized studies of interventions (NRSIs) involving pregnant women with diabetes (whether gestational, type 1, or type 2). Eligible studies were those investigating fetal monitoring in these women, such as fetal growth monitoring, fetal well‐being monitoring, or Doppler ultrasonography. Our comparisons of interest were (1) monitoring versus no monitoring/usual care, (2) monitoring versus a different type of monitoring, and (3) different regimens of the same type of monitoring. Meta‐analysis was not possible due to heterogeneity of the included studies; narrative synthesis was conducted and the Synthesis Without Meta‐analysis (SWiM) guidelines were followed. The GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluations) was used to assess the certainty of evidence for each outcome. Five studies with 4440 pregnant women with diabetes were included; two were RCTs (239 women) and three were NRSIs (4201 women). A single ultrasound growth scan over no ultrasound growth scan probably increases the risk of caesarean section (risk ratio [RR] 1.71, 95% confidence interval [CI] 1.46–2.01, 1 study, n = 2357, moderate certainty ). There is a paucity of data regarding optimal antepartum fetal monitoring for pregnant women with diabetes. Robust, high‐quality studies are urgently needed to inform clinical guidelines.
Open AccessAntepartum fetal monitoring in pregnant women with diabetes: A systematic review
Diabetes in pregnancy affects approximately 15.5% of pregnant women worldwide, the majority of these women are in low‐ and middle‐income countries. Current guidelines recommend additional fetal monitoring for pregnant women with diabetes, particularly during the third trimester, though there is limited evidence supporting these recommendations. Our objective was to identify the optimal methods and regimens for antepartum fetal monitoring for pregnant women with diabetes to inform recommendations for future clinical practice. CENTRAL, Embase, MEDLINE, and LILACs databases were searched through 23 July 2024. There were no restrictions on language or publication type. We included randomized controlled trials (RCTs) or nonrandomized studies of interventions (NRSIs) involving pregnant women with diabetes (whether gestational, type 1, or type 2). Eligible studies were those investigating fetal monitoring in these women, such as fetal growth monitoring, fetal well‐being monitoring, or Doppler ultrasonography. Our comparisons of interest were (1) monitoring versus no monitoring/usual care, (2) monitoring versus a different type of monitoring, and (3) different regimens of the same type of monitoring. Meta‐analysis was not possible due to heterogeneity of the included studies; narrative synthesis was conducted and the Synthesis Without Meta‐analysis (SWiM) guidelines were followed. The GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluations) was used to assess the certainty of evidence for each outcome. Five studies with 4440 pregnant women with diabetes were included; two were RCTs (239 women) and three were NRSIs (4201 women). A single ultrasound growth scan over no ultrasound growth scan probably increases the risk of caesarean section (risk ratio [RR] 1.71, 95% confidence interval [CI] 1.46–2.01, 1 study, n = 2357, moderate certainty ). There is a paucity of data regarding optimal antepartum fetal monitoring for pregnant women with diabetes. Robust, high‐quality studies are urgently needed to inform clinical guidelines.
- Open Access
- 7 May 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (5) , e0004575
Long-term outcomes of antenatal corticosteroids for preterm birth: An overview of systematic reviews
Antenatal corticosteroids (ACS) is a critical preterm birth intervention that reduces neonatal mortality and short-term morbidities when administered to women at risk of preterm birth <34 weeks’ gestation. While numerous systematic reviews have evaluated the effects of ACS on child health outcomes, this body of evidence has not been comprehensively assessed. This overview of systematic reviews thus aimed to comprehensively summarize the findings on the effects of ACS for preterm birth on long-term outcomes in children. We searched six electronic databases, with no date and language restrictions. Systematic reviews of randomized, non-randomized trials or observational studies that evaluated childhood health outcomes (assessed at age 12 months or older) for any ACS exposure compared to no ACS exposure, including comparisons between different types and regimens of ACS were eligible. We used the AMSTAR-2 tool to assess the quality of the included reviews. We included 19 systematic reviews. We identified a wide range of outcomes across the included reviews and categorized them as neurodevelopmental, psychological, physical growth, respiratory, cardiovascular, and survival/mortality outcomes. The reported outcomes were substantially varied in terms of operational definitions, terminology, timing of assessment, and measurement. No benefits or harms were observed for most of the reported outcomes following ACS exposure, though many outcomes had few participants. Available evidence suggested that a single course of ACS possibly has positive effects on selected neurodevelopmental outcomes. However, ACS exposure might also have adverse effects on psychological and some neurodevelopmental outcome in children born at late preterm or at term. Heterogeneity in outcome measurements and reporting, including overall confidence in results, contributes to uncertainties about long-term effect of ACS and warrants caution while interpreting the findings. Further high-quality research is required to generate robust evidence base on the effects of ACS on long-term child health outcomes.
- 7 May 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (5) , e0004575
Open AccessLong-term outcomes of antenatal corticosteroids for preterm birth: An overview of systematic reviews
Antenatal corticosteroids (ACS) is a critical preterm birth intervention that reduces neonatal mortality and short-term morbidities when administered to women at risk of preterm birth <34 weeks’ gestation. While numerous systematic reviews have evaluated the effects of ACS on child health outcomes, this body of evidence has not been comprehensively assessed. This overview of systematic reviews thus aimed to comprehensively summarize the findings on the effects of ACS for preterm birth on long-term outcomes in children. We searched six electronic databases, with no date and language restrictions. Systematic reviews of randomized, non-randomized trials or observational studies that evaluated childhood health outcomes (assessed at age 12 months or older) for any ACS exposure compared to no ACS exposure, including comparisons between different types and regimens of ACS were eligible. We used the AMSTAR-2 tool to assess the quality of the included reviews. We included 19 systematic reviews. We identified a wide range of outcomes across the included reviews and categorized them as neurodevelopmental, psychological, physical growth, respiratory, cardiovascular, and survival/mortality outcomes. The reported outcomes were substantially varied in terms of operational definitions, terminology, timing of assessment, and measurement. No benefits or harms were observed for most of the reported outcomes following ACS exposure, though many outcomes had few participants. Available evidence suggested that a single course of ACS possibly has positive effects on selected neurodevelopmental outcomes. However, ACS exposure might also have adverse effects on psychological and some neurodevelopmental outcome in children born at late preterm or at term. Heterogeneity in outcome measurements and reporting, including overall confidence in results, contributes to uncertainties about long-term effect of ACS and warrants caution while interpreting the findings. Further high-quality research is required to generate robust evidence base on the effects of ACS on long-term child health outcomes.
- Top Cited PapersOpen Access
- 4 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04106
The prevalence of long-term neurodevelopmental outcomes in preterm-born children in low- and middle-income countries: a systematic review and meta-analysis of developmental outcomes in 72 974 preterm-born children
The World Health Organization (WHO) defines preterm birth as occurring before 37 completed weeks of gestation or fewer than 259 days since the first day of a woman’s last menstrual period [1]. Globally, an estimated 13.4 million neonates are born preterm each year, with over 80% of these births occurring in sub-Saharan Africa and South […]
- 4 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04106
Top Cited PapersOpen AccessThe prevalence of long-term neurodevelopmental outcomes in preterm-born children in low- and middle-income countries: a systematic review and meta-analysis of developmental outcomes in 72 974 preterm-born children
The World Health Organization (WHO) defines preterm birth as occurring before 37 completed weeks of gestation or fewer than 259 days since the first day of a woman’s last menstrual period [1]. Globally, an estimated 13.4 million neonates are born preterm each year, with over 80% of these births occurring in sub-Saharan Africa and South […]
- Open Access
- 13 September 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (9) , e1004461
The cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: A systematic review of economic evaluations
Background: Postpartum haemorrhage (PPH) is an obstetric emergency. While PPH-related deaths are relatively rare in high-resource settings, PPH continues to be the leading cause of maternal mortality in limited-resource settings. We undertook a systematic review to identify, assess, and synthesise cost-effectiveness evidence on postpartum interventions to prevent, diagnose, or treat PPH. Methods and findings: This systematic review was prospectively registered on PROSPERO (CRD42023438424). We searched Medline, Embase, NHS Economic Evaluation Database (NHS EED), EconLit, CINAHL, Emcare, Web of Science, and Global Index Medicus between 22 June 2023 and 11 July 2024 with no date or language limitations. Full economic evaluations of any postpartum intervention for prevention, detection, or management of PPH were eligible. Study screening, data extraction, and quality assessments (using the CHEC-E tool) were undertaken independently by at least 2 reviewers. We developed narrative syntheses of available evidence for each intervention. From 3,993 citations, 56 studies were included: 33 studies of preventative interventions, 1 study assessed a diagnostic method, 17 studies of treatment interventions, 1 study comparing prevention and treatment, and 4 studies assessed care bundles. Twenty-four studies were conducted in high-income countries, 22 in upper or lower middle-income countries, 3 in low-income countries, and 7 studies involved countries of multiple income levels. Study settings, methods, and findings varied considerably. Interventions with the most consistent findings were the use of tranexamic acid for PPH treatment and using care bundles. In both cases, multiple studies predicted these interventions would either result in better health outcomes and cost savings, or better health outcomes at acceptable costs. Limitations for this review include that no ideal setting was chosen, and therefore, a transferability assessment was not undertaken. In addition, some sources of study uncertainty, such as effectiveness parameters, were interrogated to a greater degree than other sources of uncertainty. Conclusions: In this systematic review, we extracted, critically appraised, and summarised the cost-effectiveness evidence from 56 studies across 16 different interventions for the prevention, diagnosis, and treatment of PPH. Both the use of tranexamic acid as part of PPH treatment, and the use of comprehensive PPH bundles for prevention, diagnosis, and treatment have supportive cost-effectiveness evidence across a range of settings. More studies utilizing best practice principles are required to make stronger conclusions on which interventions provide the best value. Several high-priority interventions recommended by World Health Organization (WHO) such as administering additional uterotonics, non-pneumatic anti-shock garment, or uterine balloon tamponade (UBT) for PPH management require robust economic evaluations across high-, middle-, and low-resource settings.
- 13 September 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (9) , e1004461
Open AccessThe cost-effectiveness of preventing, diagnosing, and treating postpartum haemorrhage: A systematic review of economic evaluations
Background: Postpartum haemorrhage (PPH) is an obstetric emergency. While PPH-related deaths are relatively rare in high-resource settings, PPH continues to be the leading cause of maternal mortality in limited-resource settings. We undertook a systematic review to identify, assess, and synthesise cost-effectiveness evidence on postpartum interventions to prevent, diagnose, or treat PPH. Methods and findings: This systematic review was prospectively registered on PROSPERO (CRD42023438424). We searched Medline, Embase, NHS Economic Evaluation Database (NHS EED), EconLit, CINAHL, Emcare, Web of Science, and Global Index Medicus between 22 June 2023 and 11 July 2024 with no date or language limitations. Full economic evaluations of any postpartum intervention for prevention, detection, or management of PPH were eligible. Study screening, data extraction, and quality assessments (using the CHEC-E tool) were undertaken independently by at least 2 reviewers. We developed narrative syntheses of available evidence for each intervention. From 3,993 citations, 56 studies were included: 33 studies of preventative interventions, 1 study assessed a diagnostic method, 17 studies of treatment interventions, 1 study comparing prevention and treatment, and 4 studies assessed care bundles. Twenty-four studies were conducted in high-income countries, 22 in upper or lower middle-income countries, 3 in low-income countries, and 7 studies involved countries of multiple income levels. Study settings, methods, and findings varied considerably. Interventions with the most consistent findings were the use of tranexamic acid for PPH treatment and using care bundles. In both cases, multiple studies predicted these interventions would either result in better health outcomes and cost savings, or better health outcomes at acceptable costs. Limitations for this review include that no ideal setting was chosen, and therefore, a transferability assessment was not undertaken. In addition, some sources of study uncertainty, such as effectiveness parameters, were interrogated to a greater degree than other sources of uncertainty. Conclusions: In this systematic review, we extracted, critically appraised, and summarised the cost-effectiveness evidence from 56 studies across 16 different interventions for the prevention, diagnosis, and treatment of PPH. Both the use of tranexamic acid as part of PPH treatment, and the use of comprehensive PPH bundles for prevention, diagnosis, and treatment have supportive cost-effectiveness evidence across a range of settings. More studies utilizing best practice principles are required to make stronger conclusions on which interventions provide the best value. Several high-priority interventions recommended by World Health Organization (WHO) such as administering additional uterotonics, non-pneumatic anti-shock garment, or uterine balloon tamponade (UBT) for PPH management require robust economic evaluations across high-, middle-, and low-resource settings.
- Open Access
- 2 August 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (S3) , 84-91
The efficacy of antenatal corticosteroids to improve preterm newborn outcomes in low‐resource countries: Are we there yet?
- 2 August 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (S3) , 84-91
Open AccessThe efficacy of antenatal corticosteroids to improve preterm newborn outcomes in low‐resource countries: Are we there yet?
- Open Access
Stool specimen for diagnosis of pulmonary tuberculosis in adults: a systematic review
Objective To assess the diagnostic accuracy of stool specimens to diagnose pulmonary tuberculosis (PTB) in adults. Design Systematic review. Data sources MEDLINE (Ovid), Embase (Ovid), Web of Science and the Cochrane database were searched from inception to 9 March 2023–10 March 2023 using a comprehensive search strategy; reference lists of selected articles and relevant review articles were manually searched. Eligibility criteria for selecting studies Studies in English reporting diagnostic performance of stool specimens against respiratory specimens using mycobacterial culture or smear microscopy or Xpert assay to diagnose PTB in adults were eligible for this systematic review. Data extraction and synthesis Two reviewers independently screened the retrieved citations and extracted data. The risk of bias and applicability of results were assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Narrative data synthesis was performed. Results A total of 1658 citations were screened, and 28 full-text articles were assessed. Nine studies met the inclusion criteria. The reported sensitivity and specificity of stool culture varied between 21.4% and 63.9%, and 61.5% and 100%, respectively. In stool smear microscopy, sensitivities and specificities ranged from 12.1% to 53.9%, and from 79.5% to 100%, respectively. The reported sensitivities of PCR assays, including Xpert assays, ranged from 69.7% to 100%, with specificities ranging from 69.8% to 100%. Most of the studies had a low risk of bias and a low applicability concern in all domains. Conclusion This systematic review could not conclude on the diagnostic accuracy of stool specimens for PTB diagnosis in adults. Further studies are required to evaluate the accuracy of stool specimens in adults to enable meta-analyses in updates of this review as well as other systematic reviews. PROSPERO registration number CRD42021245203.
Open AccessStool specimen for diagnosis of pulmonary tuberculosis in adults: a systematic review
Objective To assess the diagnostic accuracy of stool specimens to diagnose pulmonary tuberculosis (PTB) in adults. Design Systematic review. Data sources MEDLINE (Ovid), Embase (Ovid), Web of Science and the Cochrane database were searched from inception to 9 March 2023–10 March 2023 using a comprehensive search strategy; reference lists of selected articles and relevant review articles were manually searched. Eligibility criteria for selecting studies Studies in English reporting diagnostic performance of stool specimens against respiratory specimens using mycobacterial culture or smear microscopy or Xpert assay to diagnose PTB in adults were eligible for this systematic review. Data extraction and synthesis Two reviewers independently screened the retrieved citations and extracted data. The risk of bias and applicability of results were assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Narrative data synthesis was performed. Results A total of 1658 citations were screened, and 28 full-text articles were assessed. Nine studies met the inclusion criteria. The reported sensitivity and specificity of stool culture varied between 21.4% and 63.9%, and 61.5% and 100%, respectively. In stool smear microscopy, sensitivities and specificities ranged from 12.1% to 53.9%, and from 79.5% to 100%, respectively. The reported sensitivities of PCR assays, including Xpert assays, ranged from 69.7% to 100%, with specificities ranging from 69.8% to 100%. Most of the studies had a low risk of bias and a low applicability concern in all domains. Conclusion This systematic review could not conclude on the diagnostic accuracy of stool specimens for PTB diagnosis in adults. Further studies are required to evaluate the accuracy of stool specimens in adults to enable meta-analyses in updates of this review as well as other systematic reviews. PROSPERO registration number CRD42021245203.
- Open Access
Stool specimen for diagnosis of pulmonary tuberculosis in adults: protocol for a systematic review and meta-analysis
Introduction: Tuberculosis (TB) continues to be a significant health burden, most commonly affecting the lungs and referred to as pulmonary TB (PTB). Diagnostic techniques of PTB primarily rely on expectorated sputum samples. However, the diagnostic yields are often hindered due to insufficient volume and quality of the sputum specimens. Moreover, some individuals are unable to provide sputum samples due to scanty sputum production or difficulty in coughing up and require an invasive procedure to obtain a respiratory sample, such as bronchoscopic or gastric aspiration. Thus, challenges in the acquisition of respiratory specimens warrant an alternate specimen. Therefore, this systematic review aims to evaluate the diagnostic accuracy of a stool specimen for the diagnosis of PTB in adults. Methods and analysis: We will search MEDLINE (Ovid), Embase (Ovid), Web of Science and Cochrane database from inception to April 2021 using a comprehensive search strategy. Two reviewers will independently perform screening, data extraction and quality assessment. The risk of bias assessment and applicability of results of eligible studies will be performed using the Quality of Diagnostic Accuracy Studies-2 tool. Bivariate random-effects models will be performed to calculate pooled sensitivity, specificity, positive likelihood ratio and negative likelihood ratio and diagnostic odds ratio along with 95% CI of stool specimen for each reported diagnostic method against any of the reference standard test (ie, mycobacterial culture or smear microscopy or Xpert assay using respiratory specimens). Heterogeneity between studies will be assessed by I 2 statistics and Q statistic of the χ 2 test. Ethics and dissemination: The results will be disseminated through publishing in a peer-reviewed medical journal and public presentations in relevant national and international conferences. As this is a systematic review of publicly available data, ethics approval is not required. PROSPERO registration number: CRD42021245203.
Open AccessStool specimen for diagnosis of pulmonary tuberculosis in adults: protocol for a systematic review and meta-analysis
Introduction: Tuberculosis (TB) continues to be a significant health burden, most commonly affecting the lungs and referred to as pulmonary TB (PTB). Diagnostic techniques of PTB primarily rely on expectorated sputum samples. However, the diagnostic yields are often hindered due to insufficient volume and quality of the sputum specimens. Moreover, some individuals are unable to provide sputum samples due to scanty sputum production or difficulty in coughing up and require an invasive procedure to obtain a respiratory sample, such as bronchoscopic or gastric aspiration. Thus, challenges in the acquisition of respiratory specimens warrant an alternate specimen. Therefore, this systematic review aims to evaluate the diagnostic accuracy of a stool specimen for the diagnosis of PTB in adults. Methods and analysis: We will search MEDLINE (Ovid), Embase (Ovid), Web of Science and Cochrane database from inception to April 2021 using a comprehensive search strategy. Two reviewers will independently perform screening, data extraction and quality assessment. The risk of bias assessment and applicability of results of eligible studies will be performed using the Quality of Diagnostic Accuracy Studies-2 tool. Bivariate random-effects models will be performed to calculate pooled sensitivity, specificity, positive likelihood ratio and negative likelihood ratio and diagnostic odds ratio along with 95% CI of stool specimen for each reported diagnostic method against any of the reference standard test (ie, mycobacterial culture or smear microscopy or Xpert assay using respiratory specimens). Heterogeneity between studies will be assessed by I 2 statistics and Q statistic of the χ 2 test. Ethics and dissemination: The results will be disseminated through publishing in a peer-reviewed medical journal and public presentations in relevant national and international conferences. As this is a systematic review of publicly available data, ethics approval is not required. PROSPERO registration number: CRD42021245203.